Lipid Lowering Agents Flashcards
modifiable risk factors for coronary artery disease
gout, cigarette smoking, sedentary lifestyle, high stress levels, hypertension, obesity, diabetes, untreated bacterial infections, treatment with tetracycline and fluororoentgenography
unmodifiable risk factors for coronary artery disease
genetic predisposition, age, gender
causes of hyperlipidemia
excessive dietary intake of fats; genetic alterations in fat metabolism leading to a variety of elevated fats in blood
action of lipid-lowering agents
lower serum levels of cholesterol and lipids; prevention of CAD
bile acid sequestrants
cholestyramine; decrease plasma cholesterol levels
actions of cholestyramine
used to bind with bile and prevent cholesterol from being absorbed into intestines and into blood stream
indications of cholestyramine
reduces elevated serum cholesterol in patients with primary hypercholesterolemia, pruritus associated with partial biliary obstruction
pharmacokinetics of cholestyramine
excreted through GI tract
contraindications of cholestyramine
allergy, complete biliary obstruction, abnormal intestinal function, pregnancy and lactation
adverse effects of cholestyramine
headache, fatigue, drowsiness, nausea, constipation, increased bleeding times, vitamin A and E deficiences
drug-drug interactions of cholestyramine
malabsorption of fat-soluble vitamins; thiazide diuretics, digoxin, warfarin, thyroid hormones, and corticosteroids
nursing considerations for cholestyramine
elimination patterns
what is the main side affect of cholestyramine
bloating, constipation
HMG-CoA reductase inhibtors
atorvastatin; the early rate-limiting step cellular cholesterol synthesis involves the enzyme HMG-CoA reductase. if this enzyme is blocked, serum cholesterol and LDL decrease
actions of atorvastatin
inhibits HMG-CoA, decreased serum cholesterol levels, LDLs, and triglycerides, increased HDL levels
indications of atorvastatin
adjunct to diet in the treatment of elevated cholesterol, triglycerides, and LDL; increase HDL-C in patients with primary hypercholesterolemia and two+ risk factors for CAD